Introduction
Plasma substitutes (or plasma expanders) have been used in emergent transfusion for serious blood and fluid loss (Macintyre et al. 1985) . Apart from the treatment of volume deficiency, plasma substitutes can be used in stabilizing the circulation and in diluting the blood. Conventional crystalloid (e.g. normal saline [NS] ) and colloid solutions (e.g. hydroxyethyl starch [HES] ) have been developed as plasma substitutes in clinical application Persson and Grande 2005; Nascimento et al. 2006) .
A kind of crystalloid solution, NS can be used to restore and maintain normovolemia. However, NS cannot provide sufficient colloid osmotic pressure (COP) (Nolan 2001) . In contrast, colloid solutions are more effective as plasma expanders in clinical application. Human serum albumin (HSA), a plasma protein, is considered to be the first choice for a plasma substitute. However, administration of HSA solution is controversial, as it sometimes has fatal effects (Finfer et al. 2004) . Polygeline (PG), a modified gelatin derived from animal sources, has been suspected in the recent epidemics of animal-human infections and the incidence of anaphylactoid reaction (Schortgen et al. 2001; ten Dam et al. 2001) . HES is a highly branched amylopectin attached with hydroxyethyl groups by ether linkage. It has been extensively studied for its good biocompatibility. However, there are a variety of HES solutions that are significantly different in their pharmacological properties (Messmer 1987; Frese et al. 2000; Schortgen et al. 2001) . HES 450/0.7 and HES 200/ 0.62 have high molecular weight (M w ) and high degree substitute. These properties lead to a relatively long-lasting volume effect and unfavorable influence (e.g. allergic reactions, bleeding complications). HES 70/0.5 may lead to rapid renal elimination for its low M w , and it has adverse effects on bleeding defects and platelet damage. In contrast to HES 200/0.62, HES 130/0.4 has some favorable properties, such as less bleeding complications and reduced tissue storage of HES. To whom correspondence should be addressed: Tel: +86-10-62561817; Fax: +86-10-62561813; e-mail: zgsu@home.ipe.ac.cn Typically, the conventional colloid solutions (e.g. HSA, PG and HES) are transfused in a high dosage to replace the oncotic molecules and maintain the water-retaining capacity lost from the circulation. However, the high dosage of the colloid solutions may contain trace impurities (e.g. the pyrogen) that lead to undesirable in vivo physiological response from the host (Messmer 1987; Treib et al. 1999; Schortgen et al. 2001; ten Dam et al. 2001 ). Therefore, the colloid solutions are preferred if they can be transfused in a low dosage while maintaining their plasma-expanding efficacy. Recently, polyethylene glycol-modified bovine serum albumin (PEG-BSA) was developed to achieve this purpose (Wettstein et al. 2004 ). However, its high expense may retard its clinical application as a plasma substitute.
Development of an inexpensive natural polysaccharide may be an alternative way to achieve good plasma-expanding property with less in vivo physiological side effects. Konjac glucomannan (KGM), a polysaccharide from the tubers of the plant Amorphophallus konjac (Maeda et al. 1980) , has been widely cultivated for centuries in East Asia. KGM consists of β-(1-4) linked D-mannose and D-glucose with a low degree of acetyl groups (Shimahara et al. 1975; Maeda et al. 1980; Takahashi et al. 1984) . KGM has a molecular structure that allows for a variety of chemical modifications and will not undergo the enzymatic degradation (Hashmi et al. 2007 ). Further carboxylmethylation of KGM can increase its solubility. The linear orientation and the exposed hydroxyls of D-mannose and D-glucose ( Figure 1 ) can lead to a high water-binding ability of the carboxylmethylated KGM (CKGM) solution, thereby maintaining a sufficient COP. The COP is related to the efficacy of colloidal volume expansion and is beneficial for blood flow recovery in resuscitation. Thus, the CKGM solution should be able to be transfused in a lower dosage while maintaining its plasma-expanding efficacy.
The present study was aimed at in vitro and in vivo evaluation of the CKGM solution as a potential plasma substitute. Accordingly, we measured the in vitro physiochemical properties (e.g. COP) and the in vivo hemodynamic and hemorheologic properties of the CKGM solution. Ameliorative hemorrhagic shock rabbits were used as the model animals. These physiological properties of the CKGM solution were compared with those of four commercial plasma substitutes (HSA, HES, PG and NS). Figure 2A shows the COP of the CKGM, HSA and HES solutions. Interestingly, the CKGM solution shows a much higher COP than the HSA and HES solutions. For example, 1% (w/v) CKGM solution generated a COP higher than 5% (w/v) HSA solution and 6% (w/v) HES solution. Therefore, the CKGM solution can be transfused at a much lower dosage while maintaining its plasma-expanding efficacy.
Results

The physiochemical properties of CKGM
The physical parameters of HES, HSA and CKGM are summarized in Table I and Figure 2B . As measured by membrane osmometry (M cop ), the molecular weight (M w ) of CKGM is much lower than those of HES and HSA. Moreover, the M w and the number-averaged molecular weight (M n ) of CKGM are lower than those of HES and HSA. Interestingly, the COP of the CKGM solution is exceptionally higher than those of HES and HSA. This is due to the high second virial coefficient (A 2 ) of the CKGM solution ( Figure 2B ) that is related to Modified konjac glucomannan the solvent accessible surface area (Vandegriff et al. 1997) . The low M w and large COP of the CKGM solution suggest a very large hydration volume, which agrees well with its high hydrodynamic radius (R h ) ( Table I ). The higher R h of the CKGM solution indicates its high water-binding capacity. In addition, the CKGM solution has a narrower polydispersity than HES solution.
In vitro erythrocyte deformation and aggregation indices
Normal red blood cells can pass through capillaries by deformation. This deformation ability, as reflected in the erythrocyte deformation index (EDI), can regulate blood viscosity and microcirculation. As shown in Figure 3 , the in vitro EDI in the groups treated with colloid solution was improved (P < 0.05) as compared with the NS-treated group. Moreover, the CKGMtreated group showed the highest EDI value of all the therapy groups, possibly due to the high COP of the CKGM solution.
The erythrocyte aggregation index (EAI) can reflect the ability of erythrocyte to aggregate in blood. Aggregated erythrocytes cannot deliver oxygen and could increase blood viscosity. As shown in Figure 3 , the NS-treated group showed an EAI that was lower than the groups treated with HES and PG (the neutral colloidal solutions; P < 0.05). In contrast, the NS-treated group showed an EAI that was higher than that of the groups treated with CKGM and HSA (the colloidal solutions with negative charge; P < 0.05). This is presumably due to the fact that the negative charges of the CKGM and HSA solutions increase the electrostatic repulsive forces that tend to separate cells.
In vivo hemodynamic characteristics
Mean artery pressure (MAP) is an important hemodynamic variable that is affected by blood volume (BV). As shown in Figure 4 , MAP decreased to approximately 60 mm Hg upon blood removal in all the therapy groups. During the resuscitation phase, MAP was progressively improved in all the therapy groups. The HSA and HES solutions can afford rapid restoration of MAP, but apparently lower than the CKGM solution. The PG and NS solutions showed relatively slow restoration of MAP and decreased rapidly after 2 h upon transfusion. Heart rate (HR) increased to a level higher than baseline after shock in all the therapy groups and then decreased to baseline (data not shown).
In vivo hemorheological characteristics
The change in hematocrit (Hct) is related to the plasma-expanding efficacy in 12 h and the recovery of the bleeding The second virial coefficient. f The hydrodynamic radius. Fig. 3 . The in vitro EDI and EAI of the five therapy groups. All the measurements were performed at 37°C. *: P < 0.05 versus the NS group. Fig. 4 . The mean artery pressure of the five therapy groups. Baseline: the time before surgical operation; shock: the time at the end of hemorrhagic shock; T 0 : 0 min after transfusion; T 1 : 30 min after transfusion; T 2 : 60 min after transfusion; T 3 : 120 min after transfusion. *P < 0.01 vs. shock, **P < 0.05 vs. NS, ***P < 0.01 vs. baseline.
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animals after 12 h. As shown in Figure 5 , there was a significant drop in Hct content from baseline (37-43%) to 23-29% in all the therapy groups, possibly due to the hemodilution occurring during the infusion time (a period of 10 min). The Hct content further decreased in 6 h and remained stable in 12 h in all the therapy groups. Interestingly, the CKGM-treated group showed higher Hct content in 12 h than the other four groups (P < 0.05). Moreover, there were insignificant differences in the Hct content among the other four groups. In general, the decreases from the normal to 28-30% Hct and to 20% Hct or below are termed as moderate and severe hemodilution, respectively (Kreimeier and Messmer 1996) . Interestingly, the CKGM-treated group showed moderate hemodilution (∼28% Hct) at 6 h ( Figure 5) . Presumably, the CKGM solution can improve the fluidity of blood and facilitate oxygen delivery to tissues, which in turn increase the in vivo Hct content.
The five therapy groups showed significant differences in the in vivo EDI (P < 0.05, Figure 6A ). For the NS-treated group, the EDI progressively decreased as a function of the therapy time. For the HSA-and PG-treated groups, the EDI decreased at 0.5 h and then increased at 12 h. The CKGMtreated group showed the highest EDI of all therapy groups at 0.5 h, consistent with the in vitro EDI data. However, the in vivo EDI in the CKGM-treated group progressively decreased between 12 and 24 h. The HES-treated group showed a change in the EDI similar to the CKGM-treated group. On the other hand, the NS-treated group showed an in vivo EAI that was lower at 12 h than the HES-and PG-treated groups. In contrast, the EAI of the NS-treated group at 12 h was higher than those of the HSA-and CKGM-treated groups ( Figure 6B ; P < 0.05). Moreover, the CKGM-treated group showed the lowest EAI of all the groups. Therefore, the in vivo EAI value agreed well with the in vitro EAI of all the therapy groups.
The relative blood viscosity of the HSA-treated group declined to ∼80% between 2 and 4 h. Then it progressively increased to a level higher than the baseline at 12 h ( Figure 7A ). In contrast, the CKGM-treated group showed a relative blood viscosity of ∼71% at 6 h. Then it increased to a level (∼81%) close to the baseline at 24 h. The HES-treated group showed a similar change in blood viscosity. On the other hand, the relative blood viscosity of the NS-and PG-treated groups declined rapidly between 2 and 6 h. Then it slightly increased to a level (∼67% and ∼50%, respectively) lower than the baseline at 24 h ( Figure 7A ). In addition, the HSA-treated group showed an unusual viscosity behavior.
Fibrinogen (Fib) is directly correlated with blood viscosity (Tsuda et al. 1987) . As shown in Figure 7B , the Fib content in the HSA-treated group was highest of all the therapy groups. In the CKGM-and HES-treated groups, the Fib content decreased at 6 h and then slightly increased to a level of ∼70% at 12 h. In contrast, the NS-and PG-treated groups showed lower Fib content, similar to the change in blood viscosity. Fig. 5 . The hematocrit content of the five therapy groups. Data are mean ± SD, n = 6, *: P < 0.01 vs. baseline. Fig. 6 . The in vivo EDI and EAI of the five therapy groups. All the measurements were performed at 37°C. Values are mean ± SD for the NS, HES, HSA, PG and CKGM groups, n = 6. *P < 0.05 versus the NS group.
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In vivo retention time of CKGM solution Since the physiological data are available for a period of 24 h, the in vivo retention time of the CKGM solution was measured. As shown in Figure 8 , the in vivo CKGM content displayed a slower decrease rate than the HES 130/0.4 solution (6%, w/v) (Madjdpour et al. 2005) , in spite of the low-dosage transfusion of the CKGM solution (1%, w/v). Thus, the CKGM solution showed a longer half-life time (t 1/2 , ∼8 h) than the HES solution (t 1/2 , ∼4 h). Accordingly, the CKGM solution has a longer therapy effect than the currently available HES solution.
Study of the organ dysfunction upon transfusion of CKGM solution The organs (heart, liver, spleen, kidney, lung and brain) of the CKGM-treated animals were subjected to biopsy analysis. As shown in Figure 9 , transfusion of the CKGM solution led to no physiological damage to these organs, e.g. no edema formation. Similarly, the HES and HSA therapies led to no organ dysfunction (data not shown). In contrast, transfusion of the NS solution resulted in serious damage to lungs and kidneys, e.g. edema of renal collecting ducts (Rackow et al. 1983; Zornow et al. 1988 ). Presumably, the NS solution may favor fluid shifts from the intravascular compartment to the interstitial compartment, thereby increasing the risk for edema formation. On the other hand, the colloid solutions, such as CKGM, led to a long intravascular persistence and a low risk for organ dysfunction.
Discussion
The present study was aimed at evaluation of the CKGM solution as a potential plasma substitute. The principal finding of this study is that the CKGM solution has an exceptionally high plasma-expanding efficacy. Thus, it can be transfused in a much lower dosage while maintaining efficacy comparable to other colloids, thereby providing rapid restoration of blood pressure. In addition, CKGM is derived from an inexpensive plant source, has good hemorheological and hemodynamic properties in therapy animals and leads to no organ dysfunction.
COP is related to colloidal volume-expanding efficacy and is beneficial for blood flow recovery in resuscitation (Tonnessen et al. 1993) . Recently, PEGylation of BSA has been developed to yield oncotic properties similar to those of HSA but at much lower concentration. Because less of it is needed to attain the same oncotic effect, PEG-BSA is an effective plasma expander during hemodilution and as a resuscitation fluid in hemorrhagic shock (Wettstein et al. 2004; Nanae et al. 2006) . Interestingly, the CKGM solution also shows an exceptionally high COP, and thus less CKGM is used. Therefore, the CKGM solution is effective at a low concentration like PEG-BSA and potentially has a better defined pharmacodynamic profile.
Adequate volume resuscitation is of great importance in both preoperative and critically ill patients for restoration of macro-and microcirculation (Lundberg et al. 1998; Rivers et al. 2001 ). Thus, a principal criterion for rating the efficacy of plasma expanders is the ability to maintain the circulatory volume, which is determined by its intravascular retention time ). The MAP after hemodilution could be indicative of the intravascular volume. Interestingly, the hyperoncotic CKGM solution can provide rapid restoration of blood pressure (Figure 4) . Remarkably, the restoration abil- S Li et al.
ity of MAP was maintained by the CKGM solution during the entire observation period. In contrast, the HSA and HES solutions can afford rapid restoration of MAP but apparently lower than the CKGM solution (Figure 4) . Presumably, the CKGM solution has a high R h and can be mobilized from the extravascular compartment to the intravascular compartment, thereby improving the cardiac output. Another important therapeutic avenue of plasma substitute is to improve the hemorheological properties . The hemorheological properties of the colloid solution are determined by its hemodilution capacity and inherent specific pharmacological effects on red cell aggregation, platelet function and viscosity. On the other hand, the COP of the colloid solution can determine the blood fluidity from the interstitium, thereby altering the blood viscosity, the venous return and cardiac output. The rapid infusion of the colloid solution can establish a high oncotic gradient across the microvascular space. Because the water permeability is particularly high in the postcapillary venules, the fluid influx preferentially takes place in this microvascular section, thereby resulting in local hemodilution and improving the blood fluidity. Moreover, the rapid infusion of the colloid solution can lower the whole blood viscosity and increase the cardiac output. Therefore, these improved hemorheological properties in the CKGMtreated group can increase the ability of oxygen unloading and alleviate the state of anoxic tissue. Plasma viscosity, one of the blood properties responsible for shear stress on the endothelium, is related primarily to Fib level. An unusual viscosity behavior of HSA was observed in the present study ( Figure 7A ), which may suggest some hemorheological anomaly. Also, the Fib content was higher in the HSA-treated group than those of other groups ( Figure 7B) . Presumably, the unusual viscosity behavior of the HSA solution is due partially to the increase in the Fib content. The detailed mechanism needs further investigation.
Adverse effects such as bleeding defects and pruritus have been reported in HES-treated therapy animals (Messmer 1987; Frese et al. 2000; Schortgen et al. 2001; Boldt 2004) . HES administration in a high dosage may significantly decrease the circulation of factor VIII/von Willebrand factor complex, thereby altering blood coagulation (Stump et al. 1985; Dalrymple-Hay et al. 1992) . In contrast, the CKGM solution can presumably minimize the bleeding defects for its lowdosage transfusion. In addition, HES can lead to tissue storage of the HES molecules and occurrence of pruritus, due to its high M w and wide M w distribution. In contrast, the CKGM solution can presumably minimize this side effect due to its low M w and narrow M w distribution. Future work will focus on the issue of toxicity, safety (e.g. dosage limit) and side effects (e.g. allergic reaction).
In summary, the physiological properties of the CKGM solution have been evaluated in vivo and in vitro. The present study suggests that the exceptionally high COP of the CKGM solution improves its plasma-expanding efficacy, its intravascular persistence and its hemodynamic and hemorheological properties in therapy animals. In addition, no organ dysfunction was observed in the CKGM-treated group. Thus, the CKGM solution can act as an efficient plasma substitute. Additionally, CKGM is a carboxymethylated polymer consisting of mannose and glucose, which is derived from the plant A. konjac, cultivated in East Asia. Thus, the inexpensive availability of CKGM may make it favorable in the clinical application.
Materials and methods
Purification and hydrolysis of KGM Five grams of KGM powder (Johnson Konjac Food Co. Ltd., Wuhan, China) was dissolved in 1000 mL distilled water with mechanical stirring for 3 h at room temperature. The solution was incubated at 40°C for 5 min, followed by adding 300 Ug −1 mannase for hydrolysis. After 10 min, the hydrolyzed product was treated promptly at 100°C to inactivate mannase. Finally, the solution was centrifuged and the supernatant was treated with ethanol. The precipitation was then lyophilized. 
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Carboxylmethylation of KGM The lyophilized product (1 g) was soaked in 50 mL of 90% isopropyl alcohol (volume in volume [v/v] ) at 50°C for 1 h. Then, 10 mL of 30% (w/v) NaOH solution was added gradually and incubated for 1 h. Next, 16 mL monochloroacetic acid solution (67.7%, w/v) was added and incubated for 4 h at 50°C. The straw-colored product was dissolved in water and filtered to remove impurities, followed by lyophilization of the filtrate. The reaction is represented as follows:
Determination of the physical parameters CKGM was analyzed by gel permeation chromatography coupled with a Viscotek Model 302 TDA (Postnova Analytics GmbH, Landberg, Germany) for determination of the molecular mass, polydispersity and R h . The Viscotek Model 302 TDA consists of a low-angle light-scattering instrument equipped with a 670 nm laser, a differential viscometer and a refractive index. The Viscotek Model 302 TDA is connected with an Agilent 1100 HPLC system (Triple Detection GPC). A TSK5000 column (7.5 mm × 300 mm i.d., Tosoh Bioscience LLC, Japan) was mounted on the HPLC system. The CKGM solution (100 μL) was loaded on the column and was eluted with 50 mM phosphate-buffered saline (pH 7.4) at a flow rate of 0.5mL min −1 .
Determination of colloidal osmotic pressure
The COP of the samples (∼150 μL) was measured three times at 22-24°C using a membrane colloid oncometer with a 20-kDa semipermeable membrane (BMT 923, Delta-Pharma, Pfullingen, Germany). The osmotic force to balance the chemical potential across the membrane can be calculated by the following equation (He et al. 1990 ):
where π is oncotic pressure, c is solute concentration, R is the gas constant, T is temperature in degrees, 1/M cop is the first virial coefficient (the molecular weight of solute) and A 2 is the second virial coefficient that can measure the solution ideality. This equation can be rearranged into a linear form by ignoring the higher-order virial coefficient term when A 2 is low:
M cop can be calculated by (π/c) c = 0 , which is the intercept obtained from the linear least-squares regression of π/c versus c. A 2 can be calculated from the slope of π/c versus c using the linear least-squares regression.
Animals and protocols
Adult male New Zealand white rabbits (N = 30) weighing 2.3-2.8 kg were used. The experiments were performed at the Animal Center of Peking University Health Science Center. The animals were maintained at 24 ± 1°C under a relative humidity of 50 ± 1%. The animals were fasted for 24 h with water ad libitum. Anesthesia was induced with an ear venous injection of 30 mg kg −1 sodium pentobarbital. The animals were maintained with sodium pentobarbital throughout the experiment and placed in supine position.
Procedure and protocol Randomization and Study Groups. The study was randomized but not blinded and involved five groups with six rabbits in each. The groups were defined according to the plasma expander given. The groups were the CKGM group (1% CKGM in NS), the NS group (0.9% NaCl, Zizhu Pharmaceutical, Beijing, China), the HES group (6%, Voluven 130/0.4, Fresenius, Beijing, China), the HSA group (5%, Hualan Biotechnology Inc., Hennan, China) and the PG group (4%, Wuhan Hualong Biochemical Pharmaceutical Co., Wuhan, China).
Bleeding and Volume Replacement. The right carotid artery and right jugular vein of the animals were surgically exposed. The arterial and venous catheters filled with 30 IUmL −1 heparin were inserted into the right carotid artery and the right jugular vein, respectively. The artery catheter was connected with a Y-tube for phlebotomy and for linking a BL-420E Biomedical Recorder (Chengdu TME Technology Co. Ltd., Chengdu, China) to determine the blood pressure and HR. The right jugular vein was used for the colloid infusion and blood sampling. Following a stabilization period of 10 min after anesthesia and intubation, phlebotomy was performed via the carotid artery catheter within 10 min. Total hemorrhage was 30% of the total BV, which was estimated as 5% of the body weight. Following a stabilization period of 10 min after phlebotomy, the animals received an injection of the corresponding colloid solutions. The injection was at a volume equal to the drawn BV via the jugular artery catheter within 10 min. The jugular artery catheter blood was sampled before shock and at 0.5, 2, 4, 6, 12 and 24 h after transfusion, respectively.
Preparation of the Blood Samples. The blood shed from the same rabbit was mixed with the colloid solution at the volume ratio of 1:1 for in vitro determination of EDI and EAI. Vein blood was sampled before bleeding and at 0.5, 2, 4, 6, 12 and 24 h after transfusion, respectively. The heparin (20 U/mL)-treated blood was used to measure the in vivo EDI, EAI, Hct and blood viscosity. The sodium citrate (3.28%, w/v)-treated blood was used for Fib measurement.
Determination of the Hemorheologic Parameters. Blood viscosity was measured in a capillary viscometer (Model LG-R-80B, Steellex Co., Beijing, China) at 37°C and at a shear rate of 200 s −1 . EDI and EAI were determined using a laser diffraction ektacytometer (Model LG-B-190R, Steellex Co.) at 37°C as described elsewhere (Yao et al. 2001) . Hct was measured in a capillary tube after centrifugation at 10,000 rpm for 5 min. Fib content was examined by a coagulometer (Model LG-PABER-I, Steellex Co.) using the thrombin-time method (Yao et al. 2001) .
Determination of the In Vivo CKGM Content. The sodium citrate (3.28%, w/v)-treated blood was centrifuged at 2000 rpm for 20 min and the pellet was discarded. The plasma (100 μL) was mixed with 100 μL of 2 molL −1 sulfuric acid in a sealed glass tube. The CKGM in the plasma was hydrolyzed in a boiling water bath for 24 h. The resultant mixture was neutralized by adding of 2 mol L −1 NaOH. The total sugar KGM -OH + NaOH → KGM -ONa KGM -ONa + Cl -CH 2 -COOH → KGM − O -CH 2 -COONa S Li et al.
content in the plasma before hydrolysis was determined by the phenol-sulfuric acid method (Takahashi et al. 1984 ) and served as a control. The total sugar content after CKGM hydrolysis minus the control was used to estimate the in vivo CKGM content.
Biopsy . The animals were reared on laboratory feed and injected with penicillin for 7 days. After 14 days, animals were euthanized using ether, and organs were surgically removed for histophysiological measurements. The organs, including kidney, liver, lung, spleen, heart and brain, were dissected and cleaned with NS. Then the organs were fixed by immersion in 10% (v/v) formalin solution for 24 h. Paraffin sections of the organs (6 μm thickness) were prepared for H&E (hematoxylin and eosin) staining, followed by examination through a BI-2000 medical image analysis system (Chengdu TME Technology Co. Ltd.).
Statistical analysis
Results were expressed as mean values ± SD. Statistical significance was tested using Student's unpaired t-test to compare two groups. Changes in variables from baseline or shock during volume replacement therapy were assessed in each group using Student's paired t-test. The values of P < 0.05 and P < 0.01 were considered statistically and highly statistically significant, respectively.
